News

In addition, the company issued to the investors, warrants to purchase 1.28 million shares of common stock at an exercise price of $0.65 per share. Tony Shum, chairman

Abilify is now indicated for the maintenance treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in pediatric patients (aged 10-17)

The study evaluated the outcome of 82 patients treated for chronic tendinosis using the Topaz MicroDebrider. Assessment of pain relief was monitored over a period of one to

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement

Mycamine will initially be available in the UK and across the European market shortly after this. David Denning of the University of Manchester said: “The approval of micafungin

Following the spin-off of the biotechnology company, Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including

The first of these patents covers the company’s HDL Selective Delipidation technology. HDL Selective Delipidation modifies naturally occurring HDL resulting in the creation of a substantially more effective

Ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless leg syndrome. Ropinirole hydrochloride tablets are the generic version of GlaxoSmithKline’s Requip tablets. This product will

Accolade is a high-powered 755nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser’s high repetition rates is